Cancer Genetics and Epigenetics, 2025, Vol.13, No.1, 32-40 http://medscipublisher.com/index.php/cge 40 Lan C., He M., Peng H., Shao Y., Zhu D., Zhang J., Yang F., and Huang X., 2021, Genomic profiling of advanced cervical cancer to predict response to PD-1 inhibitor combination therapy: a secondary analysis of the CLAP trial, Gynecologic Oncology, 162: S28. https://doi.org/10.1016/s0090-8258(21)00698-3 Li J., Luo H., Zhu X., Zhao J., and Chen T., 2021, Designing DNA cage-based immuno-fluorescence strategy for rapid diagnosis of clinical cervical cancer tissues, Chinese Chemical Letters, 33(2): 788-792. https://doi.org/10.1016/j.cclet.2021.08.088 Li X., Rao X., Wei M.J., Lu W., Xie X., and Wang X., 2022, Extended HPV genotyping for risk assessment of cervical intraepithelial neoplasia grade 2/3 or worse in a cohort study, Journal of the National Comprehensive Cancer Network, 20(8): 906-914. https://doi.org/10.6004/jnccn.2022.7032 Meric-Bernstam F., Brusco L., Shaw K., Horombe, C., Kopetz S., Davies M., Routbort M., Piha-Paul S., Janku F., Ueno N., Hong D., De Groot J., Ravi V., Li Y., Luthra R., Patel K., Broaddus R., Mendelsohn J., and Mills G., 2015, Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials, Journal of Clinical Oncology, 33(25): 2753-2762. https://doi.org/10.1200/JCO.2014.60.4165 Nguyen N., Choi T., Kim J., Jung M., Ko S., Shin Y., Kang I., Ha J., Kim S., and Jo Y., 2020, A 70-gene signature for predicting treatment outcome in advanced-stage cervical cancer, Molecular Therapy Oncolytics, 19: 47-56. https://doi.org/10.1016/j.omto.2020.09.001 Ramachandran D., and Dörk T., 2021, Genomic risk factors for cervical cancer, Cancers, 13(20): 5137. https://doi.org/10.3390/cancers13205137 Revathidevi S., Murugan A.K., Nakaoka H., Inoue I., and Munirajan A., 2020, APOBEC: a molecular driver in cervical cancer pathogenesis, Cancer Letters, 496: 104-116. https://doi.org/10.1016/j.canlet.2020.10.004 Roszik J., Ring K.L., Wani K.M., Lazar A.J., Yemelyanova A.V., Soliman P.T., Frumovitz M., and Jazaeri A., 2018, Gene expression analysis identifies novel targets for cervical cancer therapy, Frontiers in Immunology, 9: 2102. https://doi.org/10.3389/fimmu.2018.02102 Sawada K., Nakayama K., Nakamura K., Yoshimura Y., Razia S., Ishikawa M., Yamashita H., Ishibashi T., Sato S., and Kyo S., 2021, Clinical outcomes of genotype-matched therapy for recurrent gynecological cancers, Healthcare, 9(10): 1395. https://doi.org/10.21203/RS.3.RS-590115/V1 Services A., ILSbio L., Biomedical L., and Ma N., 2017, Integrated genomic and molecular characterization of cervical cancer, Nature, 543(7645): 378-384. https://doi.org/10.1038/NATURE21386 Shah U., Nasiruddin M., Dar S., Khan M., Akhter M., Singh N., Rabaan A., and Haque S., 2020, Emerging biomarkers and clinical significance of HPV genotyping in prevention and management of cervical cancer, Microbial Pathogenesis, 143: 104131. https://doi.org/10.1016/j.micpath.2020.104131 Takeuchi F., Kukimoto I., Li Z., Li S., Li N., Hu Z., Takahashi A., Inoue S., Yokoi S., Chen J., Hang D., Kuroda M., Matsuda F., Mizuno M., Mori S., Wu P., Tanaka N., Matsuo K., Kamatani Y., Kubo M., Ma D., and Shi Y., 2018, Genome-wide association study of cervical cancer suggests a role for ARRDC3 gene in human papillomavirus infection, Human Molecular Genetics, 28: 341-348. https://doi.org/10.1093/hmg/ddy390 Wang R., Ding K., and Zhang J., 2024, The etiology and epidemiology exploration of cervical cancer, Cancer Genetics and Epigenetics, 12(1): 8-14. https://doi.org/10.5376/cge.2024.12.0002 Zhao Q.Q., Yang S.B., Hao S.J., Chen Z.J., Tang L.H., Wu Z., Wu J.T., Xu M.Q., Ma Z.B., Zhou L., Xu J.Z., and Qin Q.S., 2024, Identification of transcriptionally-active human papillomavirus integrants through nanopore sequencing reveals viable targets for gene therapy against cervical cancer, Journal of Medical Virology, 96(6): e29769. https://doi.org/10.1002/jmv.29769
RkJQdWJsaXNoZXIy MjQ4ODYzNA==